沈阳兴齐眼药股份有限公司 关于 2023 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募 集资金管理和使用的监管要求》和深圳证券交易所印发的《深圳证券交易所上市 公司自律监管指引第 2 号——创业板上市公司规范运作》及相关格式指引的规 定，沈阳兴齐眼药股份有限公司（以下简称"公司"、"本公司"）就 2023 年半年 度募集资金存放与使用情况作如下专项报告： 一、募集资金基本情况 （一）实际募集资金金额、资金到位情况 经中国证券监督管理委员会证监许可[2021]1343 号文批准，公司向特定对 象发行人民币普通股5,763,282股，募集资金总额为人民币599,669,492.10元， 实际收到募集资金为人民币 581,870,425.73 元（已扣除承销费用（含增值税））。 上述募集资金于 2021 年 12 月 22 日全部到位，相应实收情况已经立信会计师事 务所（特殊普通合伙）审验，并出具信会师报字[2021]第 ZA15987 号验资报告。 （ ...

证券代码：300573 证券简称：兴齐眼药 公告编号：2023-042 沈阳兴齐眼药股份有限公司 关于环孢素滴眼液（Ⅱ）上市后临床试验首例受试者入组的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 沈阳兴齐眼药股份有限公司（以下简称"公司"）产品环孢素滴眼液（Ⅱ） 于近日在厦门大学附属厦门眼科中心完成了"环孢素滴眼液（Ⅱ）治疗干眼的安 全性和有效性多中心临床研究"的首例受试者入组，正式进入Ⅳ期临床试验。现 将有关内容公告如下： 一、基本情况 药物名称：环孢素滴眼液（Ⅱ） 商品名称：兹润® 注册分类：化学药品 3 类 临床试验分期：上市后临床试验 研究方法：多中心、开放性临床试验 申办方：沈阳兴齐眼药股份有限公司 二、同类药品的情况 公司环孢素滴眼液（Ⅱ）已获得《药品注册证书》（国药准字 H20203239）， 截至本公告披露日，经查询国家药品监督管理局网站，公司环孢素滴眼液（Ⅱ） 是国内唯一获得批准上市治疗干眼的环孢素眼用制剂。 三、对公司的影响 公司 0.05%环孢素滴眼液（Ⅱ）已于 2020 年 6 月获批上市，2021 年 12 月 3 日被纳入国 ...

证券代码：300573 证券简称：兴齐眼药 公告编号：2023-041 沈阳兴齐眼药股份有限公司 关于控股股东、实际控制人部分股份质押延期的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 沈阳兴齐眼药股份有限公司（以下简称："公司"）近日接到控股股东、实际 控制人刘继东先生的通知，获悉其所持有本公司的部分股份办理了质押延期购回 业务，具体事项如下： | 股东 | 是否为 控股股 东或第 一大股 | 本次延期 股份数量 | 占其所 持股份 | 占公 司总 | 是否 为限 | 是否 为补 | 原质押 | 原质押 | 延期后 质押到 | 质权 | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 东及其 | （股） | 比例 | 股本 | 售股 | 充质 | 开始日 | 到期日 | 期日 | 人 | 用途 | | | 一致行 | | | 比例 | | 押 | | | | | | | | 动人 | | | | | | | | | | | | ...

证券代码：300573 证券简称：兴齐眼药 | --- | --- | --- | --- | |------------|-------|----------------|------------------| | | □ | 特定对象调研 □ | 分析师会议 | | 投资者关系 | □ | 媒体采访 □ | 业绩说明会 | | 活动类别 | □ | 新闻发布会 | □ 路演活动 | | | □ | 现场参观 √ | 其他（电话会议） | 参与单位名称 及人员姓名 详见附件：参加交流活动人员名单 时间 2023 年 5 月 5 日 15:30-16:30（北京时间） 地点 电话会议 董事长 刘继东 副董事长、董事会秘书 张少尧 上市公司接待人 董事、总经理 高 峨 员姓名 董事、副总经理 杨 强 董事、财务总监 程亚男 全国销售总监 张辰杨 公司联合广发证券、安信证券于 2023 年 5 月 5 日召开了兴齐眼药 2022 年度及 2023 年一季度业绩交流会，公司管理层就 2022 年度及 2023 年一季度生产经营管理情况及投资者关注的问题与投资者进行了沟通和 交流内容及具体 交流。 问答记录 一、20 ...

沈阳兴齐眼药股份有限公司 2023 年第一季度报告 证券代码：300573 证券简称：兴齐眼药 公告编号：2023-023 沈阳兴齐眼药股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整、没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大 遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 3.第一季度报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 本报告期 上年同期 本报告期比上年同期增减（%） （二） 非经常性损益项目和金额 适用 □不适用 单位：元 其他符合非经常性损益定义的损益项目的具体情况 适用 □不适用 其他符合非经常性损益定义的损益项目说明：1,242,869.37 元系增值税减免和加计扣除。 | --- | --- | --- | --- | |------ ...

Financial Performance - The company reported a total revenue of CNY 1.2 billion for the fiscal year 2022, representing a year-on-year growth of 15%[29]. - The net profit attributable to shareholders was CNY 300 million, an increase of 20% compared to the previous year[29]. - The company's operating revenue for 2022 was CNY 1,249,855,370.83, representing a 21.59% increase compared to CNY 1,027,914,866.71 in 2021[34]. - The net profit attributable to shareholders for 2022 was CNY 211,684,305.31, an increase of 8.72% from CNY 194,702,374.35 in 2021[34]. - The gross margin improved to 60%, up from 55% in the previous year, due to cost optimization strategies[29]. - The company anticipates a revenue guidance of CNY 1.5 billion for 2023, representing a growth target of 25%[29]. - The total profit for the year was ¥233,718,204.58, which decreased by 4.03% year-on-year[56]. - The company achieved quarterly revenues of CNY 301,958,988.82 in Q1, CNY 298,613,531.46 in Q2, CNY 403,699,656.59 in Q3, and CNY 245,583,193.96 in Q4 of 2022[36]. Research and Development - The company is committed to improving its R&D capabilities and expanding its product pipeline to address risks related to unmet expectations in R&D projects[10]. - Research and development expenses accounted for 12% of total revenue, reflecting the company's commitment to innovation[29]. - The company intends to broaden its ophthalmic product line and increase R&D investments to stay competitive in a rapidly evolving market[8]. - The company’s R&D efforts led to the approval of new drug specifications for Moxifloxacin eye drops and the initiation of clinical trials for Voriconazole eye drops[62]. - The company is developing new drugs for retinal diseases, including SQ-21127 and SQ-129, which are in the preclinical research stage[85]. - The total R&D investment for 2022 was ¥190,199,971.05, accounting for 15.22% of operating revenue, up from 11.47% in 2021[86]. - The number of R&D personnel increased by 11.05% to 191, with a significant rise in master's degree holders by 66.15%[86]. Market Expansion and Strategy - The company aims to expand its market presence in Southeast Asia, projecting a revenue contribution of CNY 200 million from this region by 2024[29]. - The company is aware of the intensified internal competition within the pharmaceutical industry and will seek to explore new markets to sustain growth[9]. - The company plans to launch three new ophthalmic products in 2023, targeting a market share increase of 10% in the next fiscal year[29]. - The company is exploring market expansion opportunities in Southeast Asia, aiming for a 30% increase in international sales by 2024[196]. - A strategic acquisition of a local competitor is expected to enhance the company's product portfolio and increase market penetration by 15%[29]. Operational Efficiency and Cost Management - The company will actively seek new suppliers and manage procurement costs to counteract the rising costs of raw materials and ensure production efficiency[11]. - The company has implemented new technologies in production, which are expected to reduce costs by 5% in the next fiscal year[196]. - The company has established long-term stable relationships with suppliers for raw material procurement, ensuring quality and reliability[52]. - The production center will optimize production strategies to ensure sustained supply after products enter the medical insurance directory[111]. Corporate Governance and Management - The board of directors consists of 9 members, including 3 independent directors, complying with relevant laws and regulations[122]. - The supervisory board has 3 members, including 1 employee representative, meeting legal requirements[123]. - The company has established a strict internal control management system covering decision-making, asset management, procurement, and financial reporting[124]. - The company maintains independence from its controlling shareholders in business operations, personnel, assets, and financial matters[129][130][131][132][133]. - The company has a structured remuneration scheme approved by the shareholders' meeting[146]. - The total pre-tax remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 14.24 million[149]. Environmental Compliance and Social Responsibility - The company has implemented a wastewater treatment process using pre-treatment, A/O, and MBR methods, ensuring that all treated wastewater meets national and local regulatory standards[197]. - The company has invested a total of 2.1 million yuan in environmental protection in 2022, including 1.5 million yuan in environmental facilities and 400,000 yuan for hazardous waste disposal[199]. - The company has established an emergency response plan for environmental incidents, which has been filed with the local environmental bureau[197]. - The company collaborated with local welfare foundations to support 81 low-income disabled families in developing breeding projects, contributing to local economic improvement[200]. - The company has signed donation agreements to establish "Bright Future" funds aimed at enhancing rural education and infrastructure[200]. Shareholder Engagement and Profit Distribution - The company plans to distribute a cash dividend of 10 CNY per 10 shares to all shareholders, based on a total of 88,555,082 shares[16]. - The company reported a distributable profit of 494,976,789.61 RMB for the period[166]. - The cash dividend distribution plan is subject to approval at the company's 2022 annual general meeting and aligns with the company's articles of association regarding profit distribution[169]. - The independent directors confirmed that the profit distribution plan does not harm the interests of shareholders, especially minority shareholders[169]. - The company has a clear profit distribution policy that ensures the protection of shareholders' rights, particularly for minority shareholders[164].

为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 4 月 27 日（星期四）17：00 前访问 https://ir.p5w.net/zj/进入问题征集专题 页面进行提问。公司将在 2022 年度业绩说明会上，对投资者普遍关注的问题进 行回答。 证券代码：300573 证券简称：兴齐眼药 公告编号：2023-016 沈阳兴齐眼药股份有限公司 关于举行 2022 年度业绩网上说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 沈阳兴齐眼药股份有限公司（以下简称"公司"）《2022 年年度报告》及摘要 已于 2023 年 4 月 20 日在巨潮资讯网（http://www.cninfo.com.cn/）予以披露， 为让广大投资者能进一步了解公司 2022 年年度报告和 2022 年生产经营情况，公 司将于 2023 年 4 月 28 日（星期五）15:00-17:00 时举行 2022 年度业绩说明会。 本次业绩说明会将采用网络远程方式举行，投资者可登陆 ...